Trial Profile
An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary) ; MMR-varicella zoster virus vaccine (Primary)
- Indications Chickenpox; Hepatitis A; Measles; Mumps; Rubella
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 18 Nov 2008 Secondary trial identifier 'V251-066' found and added according to ClinicalTrials.gov.
- 18 Nov 2008 Actual patient number identified as 1800 from ClinicalTrials.gov.
- 18 Nov 2008 Actual trial completion date identified as January 2008 from ClinicalTrials.gov.